Please login to the form below

Not currently logged in
Email:
Password:

HTA

This page shows the latest HTA news and features for those working in and with pharma, biotech and healthcare.

ICER says Alnylam’s Onpattro should cost 90%-95% less

ICER says Alnylam’s Onpattro should cost 90%-95% less

A US health technology assessment (HTA) group has concluded that Alnylam’s just-approved Onpattro for hereditary transthyretin (hATTR) amyloidosis is priced too high.

Latest news

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    The swift decision by two of Europe’s key HTA bodies reflects the positive results demonstrated in clinical studies of guselkumab for the treatment of moderate to severe plaque psoriasis, ”said

  • Daily Brief: Trump's America First speech, Is Europe's PRIME speeding up drug approvals?

    What marks PRIME out from the FDA’s Breakthrough Therapy Designation is that it also includes input on market access issues, by allowing early conversations with health technology assessment (HTA) bodies ... Market access issues remain a major headache

  • 2018 by Darwin 2018 by Darwin

    As failed launches slow uptake and HTA rejections show us, a business model that has most of the costs of innovation but delivers few of its benefits is usually selected against

  • Transforming access in rare diseases Transforming access in rare diseases

    Project HERCULES is a unique initiative set to radically improve the way evidence is generated for HTA submissions. ... history of the disease and developing a new quality of life metric, which is essential in cost-utility based HTA processes.

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    Duchenne UK and pharma partner pilot data-sharing HTA approach. Pfizer, Roche and PTC Therapeutics are among those participating in Project Hercules. ... HTA agencies can struggle with decisions in the absence of a solid evidence base, be that data on

More from news
Approximately 35 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Stakeholder dialogue in Europe’s adaptive pathways pilot Stakeholder dialogue in Europe’s adaptive pathways pilot

    In the scientific advice sessions, involvement was limited to regulators and HTA bodies and, in some instances, clinicians and patients. ... He is a leader in Integrated Scientific Advice, combining HTA, regulatory and patient perspectives, and

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    There could be some grounds for optimism though: the PRIME scheme includes the option for HTA agencies – and patients – to be involved in giving scientific advice. ... So far, 37 sessions of scientific advice have taken place for 22 products, with

  • The valuable brand The valuable brand

    If you need evidence of this, consider how few launches achieve their goals, the frequent rejection of new products by HTAs or the increasing price pressure faced by even successful brands.

  • Drug pricing

    Healthcare terms - Drug pricing.

  • Medical education

    Healthcare terms - Medical education.

More from intelligence
Approximately 14 fully matching, plus 51 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics